SINCE THE TIME of the discovery of prostacyclin' and the elucidation of its chemical structure as prostaglandin (PG) (5Z)-9 deoxy-6, 9 a-epoxy-&APGF,,2 many synthetic prostacyclin analogues have been pre- Many structural variants of prostacyclin have been synthesized, including 5,6-dihydro analogues, exemplified by 6f3-PGI,,3-5 thia prostacyclins such as (5Z)-6,9-thia prostacyclin,6 nitrogen-containing analogues such as 9-deoxy-9a-6-nitrilo-PGF ,7 ring-expanded 5,9-epoxy derivatives such as 9-deoxy-5, 9a-epoxy-PGFI,7 and interphenylene analogues.' However, the synthesis and biological actions of stable carbocyclic analogues of prostacyclin, in which the enol-ether oxygen atom is replaced by a methylene group, has attracted much attention and has been described by several groups.9'6 Carbacyclin analogues. Carbacyclin, or (5E)-6a carbaprostaglandin '2 (figure 1, A), inhibits human platelet aggregation induced by a variety of agents including ADP, collagen, and arachidonic acid, while also inhibiting aggregation in platelet-rich plasma (PRP) obtained from several species, including the rabbit, rat, and dog.12 16 In our studies with carbacyclin,'3 this stable analogue was 0.03 times as potent as prostacyclin as an inhibitor of aggregation induced by ADP (table 1) , collagen, and arachidonic acid. As with prostacyclin, the antiaggregating activity of carbacyclin was enhanced by preincubation of platelets with theophylline, the phosphodiesterase inhibitor,'3' 1 ' indicating stimulation of cyclic AMP as its mechanism of inhibitory action. Indeed, other studies have shown an elevation of platelet cyclic AMP after incubation with the analogue. 14 Carbacyclin has been shown to be a potent inhibitor of platelet aggregation ex vivo when infused intravenously in the dog and rabbit, being 0.1 times as active as the parent, prostacyclin.'3 Likewise, this analogue was effective in vivo in reducing formation of thrombi in canine coronary arteries'6 when infused intravenously. Studies with carbacyclin in anesthetized baboons have likewise shown inhibition of platelet aggregation determined ex vivo after intravenous or intragastric administration. 17
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Studies in human PRP with 9,f-methyl-carbacyclin (ciprostene; figure 2 , B) have shown it to have comparable potency as an antiaggregating agent against several aggregating agents (table 2) . This compound is equiactive in vitro in human PRP and whole blood, and elevates platelet cyclic AMP levels. '9 Studies using further derivatives of carbacyclin have been reported, and the 15-cyclopentyl-w-pentanor carbacyclin derivative (ONO 41483, figure 1, B in vivo may also be attenuated by the release of endogenous vasoactive substances, including renin and vasopressin.27 30 Like prostacyclin, carbacyclin has comparable vasodepressor activity when administered by the intravenous or intra-arterial route, indicating minimal pulmonary inactivation of this analogue.'3 The finding that carbacyclin is a good substrate for the purified 15-hydroxy prostaglandin dehydrogenase derived from monkey lung3' lends support to the concept that these analogues fail to gain access to the enzyme in the intact lung. Like prostacyclin, these analogues will presum- ably undergo metabolism elsewhere, including in the liver.
The prevention of enzymatic inactivation of prostacyclin analogues in vivo has been attempted by substitution in both /8-and co-chains. Studies of the kinetics of 16-methyl-18,19-didehydro-carbacyclin (figure 1, D) after bolus intravenous injection in the rat have indicated a biphasic decline in plasma concentrations, with an initial half-life of 5 min.32 Although the kinetics of prostacyclin under comparable conditions was not investigated, these results suggest that the analogue does not exhibit a biologically significant longer duration of activity than prostacyclin, despite protection of the 15-hydroxy grouping from enzymatic attack. Studies in the baboon also suggest that this compound did not exhibit enhanced metabolic stability as compared with carbacyclin. 33 In a further series of carbocyclic analogues, the 15-hydroxy group was protected by modification of the cotail, e.g., by insertion of a 15-cyclohexyl grouping, while protection against /3-oxidation was afforded by insertion of an m-carboxyphenylene residue.8 Despite such modifications (figure 2, A), these prostacyclin analogues still exhibited only a short duration of action, with the hypotensive effects ranging from 0.25 to 1.2 min. Only with supramaximal doses were any differences between the duration of biological action of the analogues detected, and thus such properties have no real clinical or experimental application.
These observations with chemically stable prostacyclin analogues thus suggest that a rapid elimination of the analogues, largely independent of the rate of metabolism of the compound, is of major importance in determining the plasma levels of active drug and hence the duration of cardiovascular and antiaggregating activity in vivo. It would therefore appear that until the pharmacokinetic parameters of these analogues are fully elucidated and some mechanism of controlling the distribution of the analogue from the blood to the various tissue compartments is developed, metabolically stable prostacyclin analogues with long durations of action in vivo will remain to be identified.
Selectivity of action. A preliminary indication of the separation between platelet antiaggregating and cardiovascular actions within a particular prostacyclin analogue series can be gained from consideration of the selectivity ratio. Studies on the potency of such analogues in inhibiting human platelet aggregation in vitro and in lowering blood pressure in the anesthetized rat can be employed as primary screens for biological activity of analogues and thus, the ratio of the relative potency of effects on these parameters can readily be obtained. With the use of this ratio,'3 it has been calculated that carbacyclin has a selectivity ratio close to that of prostacyclin. A favorable ratio of activity for carbacyclin has also been reported by others, whereas the (5Z) and (1 5R)-hydroxy derivatives of carbacyclin appeared less selective than carbacyclin itself. This selectivity ratio must be interpreted with caution, since it is derived from studies in two species, and importantly, from a comparison of data obtained in vitro with that obtained in vivo. Thus, for example, modification of a structure to prevent metabolism in the body may reduce its activity in vitro compared with its parent, yet in vivo it may appear more potent as a consequence of reduced metabolism giving a seemingly high ratio and apparent low selectivity. However, platelet studies in vitro of the effects of prostacyclin and carbacyclin in PRP from man, dog, and rabbit have been predictive of the potency as an inhibitor of platelet aggregation ex vivo (table 4) .
It is clear that the most valid determination of selectivity between cardiovascular and platelet antiaggre- ADose producing 50% inhibition of platelet aggregation. Experimental data taken from Whittle et al. 11 and ex vivo human data from BO'Grady et al. 36 or CAdaikan et al.35 Results are mean ± SEM from three or four experiments during a 15 min period of intravenous infusion.
APlatelet aggregation ex vivo was induced by ADP in doses causing submaximum aggregation (3 and 5 ,M in monkey and dog, respectively) and maximum aggregation (10 and 20 ,tM, respectively).
gating actions of prostacyclin analogues is obtained from studies in which the compounds are administered in vivo and in which both parameters are measured simultaneously. For this purpose the inhibition of platelet aggregation ex vivo and concurrent cardiovascular changes have been determined in anesthetized rabbits, dogs, and monkeys.'3 To enable a more rapid preparation of samples of PRP so that platelet function could readily and continually be assessed, a rapid-spin method for the centrifugation of blood samples was developed."' With this technique, blood samples (3.0 ml) are slowly collected from a cannula inserted into a femoral vein into a plastic syringe containing trisodium citrate (3.18%, 1 volume to 9 volumes of blood), shaken gently, and transferred to two Eppendorf plastic tubes (1.5 ml). Each sample is then spun separately in a modified Eppendorf centrifuge for 2 sec (maximum centrifuge force, 10,000 g). The PRP from each tube is collected separately and 0.4 ml aliquots are transferred to the aggregometer and incubated at 370 C for 1 min before addition of sufficient ADP to produce near-maximal aggregation ( (table 5) . Further studies have been conducted with the stable analogue 9,B-methyl-carbacyclin in both anesthetized patas monkeys and greyhounds.3 After intravenous infusion in the dog, at doses having minimal action on blood pressure, both prostacyclin and 9f3-methyl carbacyclin inhibited platelet aggregation, which was determined ex vivo in samples of PRP prepared by the rapid-spin procedure (table 6). Comparison of the potency ratio for either action suggests a minimal difference between the selectivity of 9/3-methyl-carbacyclin and that of prostacyclin in this species.34 Likewise, in the monkey, in which both prostacyclin and 9,3-methyl-carbacyclin were less potent with respect to both parameters compared with in the dog, there was no significant difference between the potency ratios and hence selectivity of the compounds ( readily demonstrated in certain species and preparations of platelet aggregation. Studies with the 16-substituted carbacyclin derivative iloprost ( figure 1, D) in the anesthetized cat indicate that the decrease in peripheral platelet count after coronary ligation can be abolished by doses having no effect on blood pressure. 22 Results of studies with this derivative in the baboon during intravenous infusion have indicated that platelet aggregation ex vivo could be inhibited with variable effects on blood pressure and heart rate.33 Investigation of the hypotensive activity after bolus injection in the baboon have suggested selectivity of action of iloprost away from the cardiovascular actions of carbacyclin.33 Comparative studies with this analogue and with prostacyclin on formation of thrombi in an extracorporeal circuit in the anesthetized rat could not, however, demonstrate any disassociation between the antiaggregatory and vasodepressor actions.24
Studies in man. In a preliminary evaluation in human volunteers, intravenous infusion of carbacyclin inhibited platelet aggregation ex vivo yet had no effect on blood pressure or heart rate. 35 Since concurrent studies with prostacyclin in these subjects were not undertaken, the extent of this selectivity of action in man could not be assessed. After oral administration of carbacyclin (25 mg) in two subjects in a dose sufficient to cause approximately 68% inhibition of platelet aggregation ex vivo (determined 30 to 90 min later), a marked rise in heart rate was observed, along with headache and flushing of rapid onset. 35 In studies in human volunteers, the analogue 15-cyclopentyl carbacyclin (ONO 41483; figure 1, B) , infused intravenously in the maximum tolerated dose (2.5 ng kg-'min-'), caused a 27% inhibition of platelet aggregation ex vivo.21 Higher doses, both by the intravenous and oral route, produced more substantial inhibition of platelet aggregation, but also induced side effects including flushing of the face and limbs, headache, and phlebitis,2' effects similar to those observed with high doses of prostacyclin. 36 In a placebo-controlled study in six patients with peripheral vascular disease, intravenous infusion of the 16-methyl derivative iloprost ( figure 1, A) in doses of 0.5 to 3 ng kg-'min-' for 2 to 4 hr did not alter systemic arterial blood pressure or heart rate, nor did it increase blood flow in the calf muscle or extremities.37 At higher doses that inhibited platelet aggregation ex vivo, side effects of facial flushing and headache were observed.37 In a further study during intravenous infusion of iloprost (4 to 8 ng-lkg-'min-1) for 72 hr in nine patients with peripheral vascular disease, marked vasodilation but only a small fall in blood pressure was reported, but a high incidence of side effects (including headache and vomiting) was noted. An increase in urine output, glomerular filtration, and kallikrein excretion was also found, with a decrease in tubular reabsorptions of sodium and water and serum angiotensin-converting activity after infusion of iloprost.38
In a double-blind placebo-controlled comparison of the effects of epoprostenol (prostacyclin) and the analogue 9/3-methyl-carbacyclin (figure 2, B; ciprostene) in healthy volunteers, the two drugs exhibited comparable profiles of pharmacologic activity.'9 During intravenous infusion, 9/3-methyl-carbacyclin (150 to 600 ng kg-lmin-m) significantly displaced the dose-response curve for ADP-induced platelet aggregation ex vivo, being 0.01 times as active as prostacyclin. As with prostacyclin, elevation in heart rate was only observed at the highest rate of infusion, while no change in systolic or diastolic blood pressure or left ventricular ejection time was observed with either compound in the dose range studied. A greater incidence of facial flushing was observed with prostacyclin than with 9/3-methyl-carbacyclin in the lower dose range, while headache was only noted at the highest rate of infusion of 9,3-methyl-carbacyclin.'9 The pharmacodynamic effects and duration of action of 9/-methyl-carbacyclin and prostacyclin in man are thus comparable, with the analogue being 100 times less active.
The mechanisms underlying peripheral vasodilation, as demonstrated by facial flushing or increased blood flow to the extremities in the absence of a marked fall in blood pressure, as seen with prostacydin, 9/3-methyl-carbacyclin, or other analogues, warrant further investigation and point to potential therapeutic utilities of these compounds, including the treatment of peripheral vascular diseases. Although the carbacyclin analogues described thus far offer 
